ReP USP - Resultado da busca

Artigo de periodico
HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents (2024)
Waitman, Karoline de Barros ; Almeida, Larissa Costa de ; Primi, Marina Candido ; Carlos, Jorge Antonio Elias Godoy ; Ruiz, Claudia; Kronenberger, Thales ; Laufer, Stefan; Goettert, Marcia Ines; Poso, Antti ; Vassiliades, Sandra Valeria ; Souza, Vinicius Albuquerque Moreira de ; Toledo, Mônica Franco Zannini Junqueira ; Hassimotto, Neuza Mariko Aymoto ; Cameron, Michael D; Bannister, Thomas D; Lotufo, Leticia Veras Costa ; Machado Neto, João Agostinho ; Tavares, Maurício T.; Parise Filho, Roberto
Fonte: European Journal of Medicinal Chemistry. Unidades: FCF, ICB
Assuntos: ANTINEOPLÁSICOS, HIBRIDIZAÇÃO, CÉLULAS CULTIVADAS DE TUMOR, PROTEÍNAS, PURINAS, CITOTOXINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WAITMAN, Karoline de Barros et al. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. European Journal of Medicinal Chemistry, v. 263, p. 1-18 art. 115935, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ejmech.2023.115935. Acesso em: 10 jul. 2024.
APA
Waitman, K. de B., Almeida, L. C. de, Primi, M. C., Carlos, J. A. E. G., Ruiz, C., Kronenberger, T., et al. (2024). HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. European Journal of Medicinal Chemistry, 263, 1-18 art. 115935. doi:10.1016/j.ejmech.2023.115935
NLM
Waitman K de B, Almeida LC de, Primi MC, Carlos JAEG, Ruiz C, Kronenberger T, Laufer S, Goettert MI, Poso A, Vassiliades SV, Souza VAM de, Toledo MFZJ, Hassimotto NMA, Cameron MD, Bannister TD, Lotufo LVC, Machado Neto JA, Tavares MT, Parise Filho R. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents [Internet]. European Journal of Medicinal Chemistry. 2024 ; 263 1-18 art. 115935.[citado 2024 jul. 10 ] Available from: https://dx.doi.org/10.1016/j.ejmech.2023.115935
Vancouver
Waitman K de B, Almeida LC de, Primi MC, Carlos JAEG, Ruiz C, Kronenberger T, Laufer S, Goettert MI, Poso A, Vassiliades SV, Souza VAM de, Toledo MFZJ, Hassimotto NMA, Cameron MD, Bannister TD, Lotufo LVC, Machado Neto JA, Tavares MT, Parise Filho R. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents [Internet]. European Journal of Medicinal Chemistry. 2024 ; 263 1-18 art. 115935.[citado 2024 jul. 10 ] Available from: https://dx.doi.org/10.1016/j.ejmech.2023.115935
Artigo de periodico
SETDB1 as a cancer target: challenges and perspectives in drug design (2024)
Hassanie, Haifa ; Penteado, André Berndt ; Almeida, Larissa Costa de ; Calil, Raisa Ludmila; Emery, Flavio da Silva ; Lotufo, Leticia Veras Costa ; Trossini, Gustavo Henrique Goulart
Fonte: RSC Medicinal Chemistry. Unidades: FCFRP, ICB, FCF
Assuntos: NEOPLASIAS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HASSANIE, Haifa et al. SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, v. 15, n. 5, p. 1424-1451, 2024Tradução . . Disponível em: https://dx.doi.org/10.1039/D3MD00366C. Acesso em: 10 jul. 2024.
APA
Hassanie, H., Penteado, A. B., Almeida, L. C. de, Calil, R. L., Emery, F. da S., Lotufo, L. V. C., & Trossini, G. H. G. (2024). SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, 15( 5), 1424-1451. doi:10.1039/D3MD00366C
NLM
Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Lotufo LVC, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 jul. 10 ] Available from: https://dx.doi.org/10.1039/D3MD00366C
Vancouver
Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Lotufo LVC, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 jul. 10 ] Available from: https://dx.doi.org/10.1039/D3MD00366C
Trabalho de evento-resumo
Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models (2023)
Carlos, Jorge Antonio Elias Godoy ; Almeida, Larissa Costa de ; Lima, Keli; Tavares, Maurício Temotheo ; Waitman, Karoline de Barros ; Lotufo, Leticia Veras Costa ; Parise Filho, Roberto ; Machado Neto, João Agostinho
Fonte: Anais. Nome do evento: Reunião Anual da Sociedade Brasileira de Química/RASBQ. Unidades: ICB, FCF
Assunto: LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models. 2023, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2023. Disponível em: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf. Acesso em: 10 jul. 2024.
APA
Carlos, J. A. E. G., Almeida, L. C. de, Lima, K., Tavares, M. T., Waitman, K. de B., Lotufo, L. V. C., et al. (2023). Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
NLM
Carlos JAEG, Almeida LC de, Lima K, Tavares MT, Waitman K de B, Lotufo LVC, Parise Filho R, Machado Neto JA. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models [Internet]. Anais. 2023 ;[citado 2024 jul. 10 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
Vancouver
Carlos JAEG, Almeida LC de, Lima K, Tavares MT, Waitman K de B, Lotufo LVC, Parise Filho R, Machado Neto JA. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models [Internet]. Anais. 2023 ;[citado 2024 jul. 10 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
Trabalho de evento-resumo
Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment (2023)
Waitman, Karoline de Barros ; Tavares, Maurício Temotheo ; Almeida, Larissa Costa de ; Carlos, Jorge Antonio Elias Godoy ; Kronenberger, Thales ; Toledo, Mônica Franco Zannini Junqueira ; Lotufo, Leticia Veras Costa ; Machado Neto, João Agostinho ; Parise Filho, Roberto
Fonte: Anais. Nome do evento: Reunião Anual da Sociedade Brasileira de Química/RASBQ. Unidades: FCF, ICB
Assuntos: NEOPLASIAS, HIBRIDIZAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WAITMAN, Karoline de Barros et al. Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. 2023, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2023. Disponível em: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf. Acesso em: 10 jul. 2024.
APA
Waitman, K. de B., Tavares, M. T., Almeida, L. C. de, Carlos, J. A. E. G., Kronenberger, T., Toledo, M. F. Z. J., et al. (2023). Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
NLM
Waitman K de B, Tavares MT, Almeida LC de, Carlos JAEG, Kronenberger T, Toledo MFZJ, Lotufo LVC, Machado Neto JA, Parise Filho R. Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2023 ;[citado 2024 jul. 10 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
Vancouver
Waitman K de B, Tavares MT, Almeida LC de, Carlos JAEG, Kronenberger T, Toledo MFZJ, Lotufo LVC, Machado Neto JA, Parise Filho R. Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2023 ;[citado 2024 jul. 10 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
Trabalho de evento-resumo
Antiproliferative, anti-leshmanial and metabolomics prospecting of Brazilian cyanobacteria (2023)
Silva, Francisco Henrique Santana da; Jesus, Leonardo Santos de ; Weiss, Márcio Barczyszyn ; Soares, Sandra Regina Castro ; Gonçalves, Camila Mariano Comin ; Domingos, Helori Vanni ; Lotufo, Leticia Veras Costa ; Lindoso, Jose Angelo Lauletta ; Berlinck, Roberto Gomes de Souza ; Crnkovic, Camila Manoel
Fonte: Proceedings. Nome do evento: Brazilian Conference on Natural Products - BNCP. Unidades: FM, ICB, IQSC, FCF, ESALQ
Assuntos: PRODUTOS NATURAIS, METABOLÔMICA, BIOENSAIOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Francisco Henrique Santana da et al. Antiproliferative, anti-leshmanial and metabolomics prospecting of Brazilian cyanobacteria. 2023, Anais.. Campinas: Faculdade de Medicina, Universidade de São Paulo, 2023. Disponível em: https://proceedings.science/bcnp-series/bcnp-2023/papers/antiproliferative-anti-leshmanial-and-metabolomics-prospecting-of-brazilian-cyan?lang=en. Acesso em: 10 jul. 2024.
APA
Silva, F. H. S. da, Jesus, L. S. de, Weiss, M. B., Soares, S. R. C., Gonçalves, C. M. C., Domingos, H. V., et al. (2023). Antiproliferative, anti-leshmanial and metabolomics prospecting of Brazilian cyanobacteria. In Proceedings. Campinas: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://proceedings.science/bcnp-series/bcnp-2023/papers/antiproliferative-anti-leshmanial-and-metabolomics-prospecting-of-brazilian-cyan?lang=en
NLM
Silva FHS da, Jesus LS de, Weiss MB, Soares SRC, Gonçalves CMC, Domingos HV, Lotufo LVC, Lindoso JAL, Berlinck RG de S, Crnkovic CM. Antiproliferative, anti-leshmanial and metabolomics prospecting of Brazilian cyanobacteria [Internet]. Proceedings. 2023 ;[citado 2024 jul. 10 ] Available from: https://proceedings.science/bcnp-series/bcnp-2023/papers/antiproliferative-anti-leshmanial-and-metabolomics-prospecting-of-brazilian-cyan?lang=en
Vancouver
Silva FHS da, Jesus LS de, Weiss MB, Soares SRC, Gonçalves CMC, Domingos HV, Lotufo LVC, Lindoso JAL, Berlinck RG de S, Crnkovic CM. Antiproliferative, anti-leshmanial and metabolomics prospecting of Brazilian cyanobacteria [Internet]. Proceedings. 2023 ;[citado 2024 jul. 10 ] Available from: https://proceedings.science/bcnp-series/bcnp-2023/papers/antiproliferative-anti-leshmanial-and-metabolomics-prospecting-of-brazilian-cyan?lang=en
Trabalho de evento-resumo
Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment (2022)
Waitman, Karoline de Barros ; Tavares, Maurício Temotheo ; Almeida, Larissa Costa de ; Toledo, Mônica Franco Zannini Junqueira ; Machado Neto, João Agostinho ; Lotufo, Leticia Veras Costa ; Parise Filho, Roberto
Fonte: Anais. Nome do evento: Reunião Anual da Sociedade Brasileira de Química. Unidades: FCF, ICB
Assuntos: NEOPLASIAS, PURINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WAITMAN, Karoline de Barros et al. Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. 2022, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2022. Disponível em: http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf. Acesso em: 10 jul. 2024.
APA
Waitman, K. de B., Tavares, M. T., Almeida, L. C. de, Toledo, M. F. Z. J., Machado Neto, J. A., Lotufo, L. V. C., & Parise Filho, R. (2022). Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf
NLM
Waitman K de B, Tavares MT, Almeida LC de, Toledo MFZJ, Machado Neto JA, Lotufo LVC, Parise Filho R. Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2022 ;[citado 2024 jul. 10 ] Available from: http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf
Vancouver
Waitman K de B, Tavares MT, Almeida LC de, Toledo MFZJ, Machado Neto JA, Lotufo LVC, Parise Filho R. Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2022 ;[citado 2024 jul. 10 ] Available from: http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf
Trabalho de evento-resumo periodico
Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models (2022)
Carlos, Jorge Antonio Elias Godoy ; Almeida, L C; Lima, K; Tavares, M T; Lotufo, Leticia Veras Costa ; Parise Filho, Roberto ; Machado Neto, João Agostinho
Fonte: Hematology, Transfusion and Cell Therapy. Nome do evento: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular (HEMO). Unidades: ICB, FCF
Assunto: ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models. Hematology, Transfusion and Cell Therapy. Amsterdam: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2022.09.265. Acesso em: 10 jul. 2024. , 2022
APA
Carlos, J. A. E. G., Almeida, L. C., Lima, K., Tavares, M. T., Lotufo, L. V. C., Parise Filho, R., & Machado Neto, J. A. (2022). Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models. Hematology, Transfusion and Cell Therapy. Amsterdam: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1016/j.htct.2022.09.265
NLM
Carlos JAEG, Almeida LC, Lima K, Tavares MT, Lotufo LVC, Parise Filho R, Machado Neto JA. Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44 s157-s158.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.htct.2022.09.265
Vancouver
Carlos JAEG, Almeida LC, Lima K, Tavares MT, Lotufo LVC, Parise Filho R, Machado Neto JA. Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44 s157-s158.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.htct.2022.09.265
Trabalho de evento-resumo periodico
A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells (2022)
Jaeg, Carlos; Almeida, LC; Lima, K; Tavares, M. T; Waitman, K. B; Lotufo, Leticia Veras Costa ; Parise Filho, Roberto ; Machado Neto, João Agostinho
Fonte: Hematology, Transfusion and Cell Therapy. Nome do evento: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular (HEMO). Unidades: ICB, FCF
Assuntos: INIBIDORES DE ENZIMAS, APOPTOSE, LEUCEMIA MIELOIDE AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JAEG, Carlos et al. A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells. Hematology, Transfusion and Cell Therapy. Amsterdam: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2022.09.267. Acesso em: 10 jul. 2024. , 2022
APA
Jaeg, C., Almeida, L. C., Lima, K., Tavares, M. T., Waitman, K. B., Lotufo, L. V. C., et al. (2022). A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells. Hematology, Transfusion and Cell Therapy. Amsterdam: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1016/j.htct.2022.09.267
NLM
Jaeg C, Almeida LC, Lima K, Tavares MT, Waitman KB, Lotufo LVC, Parise Filho R, Machado Neto JA. A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44 s158-s159.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.htct.2022.09.267
Vancouver
Jaeg C, Almeida LC, Lima K, Tavares MT, Waitman KB, Lotufo LVC, Parise Filho R, Machado Neto JA. A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44 s158-s159.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.htct.2022.09.267
Artigo de periodico
Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors (2021)
Tavares, Maurício Temotheo ; Almeida, Larissa Costa de ; Kronenberger, Thales ; Ferreira, Glaucio Monteiro ; Divitiis, Thainá Fujii de ; Toledo, Mônica Franco Zannini Junqueira ; Hassimotto, Neuza Mariko Aymoto ; Machado Neto, João Agostinho ; Lotufo, Leticia Veras Costa ; Parise Filho, Roberto
Fonte: Bioorganic and Medicinal Chemistry. Unidades: FCF, ICB, PRÓ-G
Assuntos: CITOTOXICIDADE IMUNOLÓGICA, ENZIMAS, FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, APOPTOSE, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TAVARES, Maurício Temotheo et al. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry, v. 35, p. 1-42 art. 116085, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.bmc.2021.116085. Acesso em: 10 jul. 2024.
APA
Tavares, M. T., Almeida, L. C. de, Kronenberger, T., Ferreira, G. M., Divitiis, T. F. de, Toledo, M. F. Z. J., et al. (2021). Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry, 35, 1-42 art. 116085. doi:10.1016/j.bmc.2021.116085
NLM
Tavares MT, Almeida LC de, Kronenberger T, Ferreira GM, Divitiis TF de, Toledo MFZJ, Hassimotto NMA, Machado Neto JA, Lotufo LVC, Parise Filho R. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors [Internet]. Bioorganic and Medicinal Chemistry. 2021 ; 35 1-42 art. 116085.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.bmc.2021.116085
Vancouver
Tavares MT, Almeida LC de, Kronenberger T, Ferreira GM, Divitiis TF de, Toledo MFZJ, Hassimotto NMA, Machado Neto JA, Lotufo LVC, Parise Filho R. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors [Internet]. Bioorganic and Medicinal Chemistry. 2021 ; 35 1-42 art. 116085.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.bmc.2021.116085
Artigo de periodico
Survivin modulation in the antimelanoma activity of prodiginines (2020)
Branco, Paola Cristina; Pontes, Cristine A. ; Teixeira, Paula Rezende ; Rigo, Pep Amengual ; Fernandes, Débora Kristina Alves ; Maria-Engler, Silvya Stuchi ; Silva, Alison Batista da ; Pessoa, Otilia Deusdênia Loiola ; Jimenez, Paula C. ; Mollasalehi, Niloufar ; Chapman, Eli ; Guallar, Victor ; Machado Neto, João Agostinho ; Lotufo, Leticia Veras Costa
Fonte: European Journal of Pharmacology. Unidades: BIOTECNOLOGIA, FCF, ICB
Assuntos: PROTEÍNAS, APOPTOSE, MELANOMA, METASTASE NEOPLÁSICA, QUIMIOTERAPIA, PRODUTOS NATURAIS, CITOTOXICIDADE IMUNOLOGICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRANCO, Paola Cristina et al. Survivin modulation in the antimelanoma activity of prodiginines. European Journal of Pharmacology, v. 888, p. 1-10 art. 173465, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ejphar.2020.173465. Acesso em: 10 jul. 2024.
APA
Branco, P. C., Pontes, C. A., Teixeira, P. R., Rigo, P. A., Fernandes, D. K. A., Maria-Engler, S. S., et al. (2020). Survivin modulation in the antimelanoma activity of prodiginines. European Journal of Pharmacology, 888, 1-10 art. 173465. doi:10.1016/j.ejphar.2020.173465
NLM
Branco PC, Pontes CA, Teixeira PR, Rigo PA, Fernandes DKA, Maria-Engler SS, Silva AB da, Pessoa ODL, Jimenez PC, Mollasalehi N, Chapman E, Guallar V, Machado Neto JA, Lotufo LVC. Survivin modulation in the antimelanoma activity of prodiginines [Internet]. European Journal of Pharmacology. 2020 ; 888 1-10 art. 173465.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ejphar.2020.173465
Vancouver
Branco PC, Pontes CA, Teixeira PR, Rigo PA, Fernandes DKA, Maria-Engler SS, Silva AB da, Pessoa ODL, Jimenez PC, Mollasalehi N, Chapman E, Guallar V, Machado Neto JA, Lotufo LVC. Survivin modulation in the antimelanoma activity of prodiginines [Internet]. European Journal of Pharmacology. 2020 ; 888 1-10 art. 173465.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ejphar.2020.173465
Trabalho de evento-resumo periodico
Prodiginines as antimelanoma agents: mechanism of action, chemoresistance overcoming and target determination (2020)
Branco, Paola C. ; Aráujo, Cristine P.; Teixeira, Paula Rezende ; Bauermeister, Anelize ; Alves, Débora K.; Jimenez, Paula C. ; Maria-Engler, Silvya Stuchi ; Machado Neto, João Agostinho ; Lopes, Norberto P. ; Lotufo, Leticia Veras Costa
Fonte: Marine Drugs. Nome do evento: International Symposium on Marine Natural Products. Unidades: FCF, ICB, FCFRP
Assuntos: MELANOMA, ANTINEOPLÁSICOS, PRODUTOS NATURAIS, PIGMENTOS BIOLÓGICOS, CITOTOXINAS, CÉLULAS MORTAS, APOPTOSE, QUIMIOTERÁPICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRANCO, Paola C. et al. Prodiginines as antimelanoma agents: mechanism of action, chemoresistance overcoming and target determination. Marine Drugs. Basel: MDPI AG. Disponível em: https://doi.org/10.3390/md18010040. Acesso em: 10 jul. 2024. , 2020
APA
Branco, P. C., Aráujo, C. P., Teixeira, P. R., Bauermeister, A., Alves, D. K., Jimenez, P. C., et al. (2020). Prodiginines as antimelanoma agents: mechanism of action, chemoresistance overcoming and target determination. Marine Drugs. Basel: MDPI AG. doi:10.3390/md18010040
NLM
Branco PC, Aráujo CP, Teixeira PR, Bauermeister A, Alves DK, Jimenez PC, Maria-Engler SS, Machado Neto JA, Lopes NP, Lotufo LVC. Prodiginines as antimelanoma agents: mechanism of action, chemoresistance overcoming and target determination [Internet]. Marine Drugs. 2020 ; 18( 1): 112-113.[citado 2024 jul. 10 ] Available from: https://doi.org/10.3390/md18010040
Vancouver
Branco PC, Aráujo CP, Teixeira PR, Bauermeister A, Alves DK, Jimenez PC, Maria-Engler SS, Machado Neto JA, Lopes NP, Lotufo LVC. Prodiginines as antimelanoma agents: mechanism of action, chemoresistance overcoming and target determination [Internet]. Marine Drugs. 2020 ; 18( 1): 112-113.[citado 2024 jul. 10 ] Available from: https://doi.org/10.3390/md18010040
Artigo de periodico
Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline (2020)
Apolinário, Alexsandra Conceição ; Hirata, Amanda Soares ; Miguel, Rodrigo dos Anjos ; Lotufo, Leticia Veras Costa ; Pessoa Junior, Adalberto ; Clair, James J. La ; Fenical, William ; Lopes, Luciana Biagini
Fonte: Nanomedicine. Unidades: ICB, FCF
Assuntos: FARMACOLOGIA, NEOPLASIAS MAMÁRIAS, NANOTECNOLOGIA, ANTINEOPLÁSICOS, QUIMIOTERÁPICOS, MELANOMA, FARMACOS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
APOLINÁRIO, Alexsandra Conceição et al. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline. Nanomedicine, v. 15, n. 26, p. 2539–2542, 2020Tradução . . Disponível em: https://doi.org/10.2217/nnm-2020-0290. Acesso em: 10 jul. 2024.
APA
Apolinário, A. C., Hirata, A. S., Miguel, R. dos A., Lotufo, L. V. C., Pessoa Junior, A., Clair, J. J. L., et al. (2020). Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline. Nanomedicine, 15( 26), 2539–2542. doi:10.2217/nnm-2020-0290
NLM
Apolinário AC, Hirata AS, Miguel R dos A, Lotufo LVC, Pessoa Junior A, Clair JJL, Fenical W, Lopes LB. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline [Internet]. Nanomedicine. 2020 ; 15( 26): 2539–2542.[citado 2024 jul. 10 ] Available from: https://doi.org/10.2217/nnm-2020-0290
Vancouver
Apolinário AC, Hirata AS, Miguel R dos A, Lotufo LVC, Pessoa Junior A, Clair JJL, Fenical W, Lopes LB. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline [Internet]. Nanomedicine. 2020 ; 15( 26): 2539–2542.[citado 2024 jul. 10 ] Available from: https://doi.org/10.2217/nnm-2020-0290
Artigo de periodico
Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models (2020)
Giacone, Daniela Veronesi ; Dartora, Vanessa Franco Carvalho ; Matos, Jenyffer Kelly Rocha De ; Passos, Julia Sapienza ; Miranda, Daniel Augusto Gomes ; Oliveira, Erica Aparecida de ; Silveira, Edilberto R. ; Lotufo, Leticia Veras Costa ; Maria-Engler, Silvya Stuchi ; Lopes, Luciana Biagini
Fonte: Journal of Biological Macromolecules. Unidades: ICB, FCF
Assuntos: NEOPLASIAS, NEOPLASIAS EMBRIONÁRIAS DE CÉLULAS GERMINATIVAS, PELE, ALGINATOS, MELANOMA, QUITOSANA, POLISSACARÍDEOS, CITOTOXINAS, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIACONE, Daniela Veronesi et al. Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models. Journal of Biological Macromolecules, v. 165, p. 1055-1065, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ijbiomac.2020.09.167. Acesso em: 10 jul. 2024.
APA
Giacone, D. V., Dartora, V. F. C., Matos, J. K. R. D., Passos, J. S., Miranda, D. A. G., Oliveira, E. A. de, et al. (2020). Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models. Journal of Biological Macromolecules, 165, 1055-1065. doi:10.1016/j.ijbiomac.2020.09.167
NLM
Giacone DV, Dartora VFC, Matos JKRD, Passos JS, Miranda DAG, Oliveira EA de, Silveira ER, Lotufo LVC, Maria-Engler SS, Lopes LB. Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models [Internet]. Journal of Biological Macromolecules. 2020 ; 165 1055-1065.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ijbiomac.2020.09.167
Vancouver
Giacone DV, Dartora VFC, Matos JKRD, Passos JS, Miranda DAG, Oliveira EA de, Silveira ER, Lotufo LVC, Maria-Engler SS, Lopes LB. Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models [Internet]. Journal of Biological Macromolecules. 2020 ; 165 1055-1065.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ijbiomac.2020.09.167
Artigo de periodico
Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting (2019)
Dartora, Vanessa Franco Carvalho ; Salata, Giovanna Cassone ; Matos, Jenyffer Kelly Rocha de ; Fernandez, Sandra Costa; Chorilli, Marlus ; Steiner, Alexandre Alarcon ; Araujo, Gabriel Lima Barros de ; Silveira, Edilberto Rocha ; Lotufo, Leticia Veras Costa ; Lopes, Luciana Biagini
Fonte: International Journal of Pharmaceutics. Unidades: ICB, FCF
Assuntos: FARMACOLOGIA, IMUNOLOGIA, NEOPLASIAS MAMÁRIAS, CITOTOXICIDADE IMUNOLÓGICA, QUITOSANA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DARTORA, Vanessa Franco Carvalho et al. Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting. International Journal of Pharmaceutics, v. 567, p. 13 , 2019Tradução . . Disponível em: https://doi.org/10.1016/j.ijpharm.2019.118460. Acesso em: 10 jul. 2024.
APA
Dartora, V. F. C., Salata, G. C., Matos, J. K. R. de, Fernandez, S. C., Chorilli, M., Steiner, A. A., et al. (2019). Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting. International Journal of Pharmaceutics, 567, 13 . doi:10.1016/j.ijpharm.2019.118460
NLM
Dartora VFC, Salata GC, Matos JKR de, Fernandez SC, Chorilli M, Steiner AA, Araujo GLB de, Silveira ER, Lotufo LVC, Lopes LB. Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting [Internet]. International Journal of Pharmaceutics. 2019 ; 567 13 .[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ijpharm.2019.118460
Vancouver
Dartora VFC, Salata GC, Matos JKR de, Fernandez SC, Chorilli M, Steiner AA, Araujo GLB de, Silveira ER, Lotufo LVC, Lopes LB. Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting [Internet]. International Journal of Pharmaceutics. 2019 ; 567 13 .[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ijpharm.2019.118460
Artigo de periodico
Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models (2017)
Carvalho, Vanessa F. M; Migotto, Amanda; Giacone, Daniela V; Lemos, Débora P. de; Zanoni, Thalita B; Maria-Engler, Silvya Stuchi ; Lotufo, Leticia Veras Costa ; Lopes, Luciana Biagini
Fonte: European Journal of Pharmaceutical Sciences. Unidades: FCF, ICB
Assuntos: PELE, MELANOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARVALHO, Vanessa F. M et al. Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models. European Journal of Pharmaceutical Sciences, v. 109, p. 131-143, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2017.07.023. Acesso em: 10 jul. 2024.
APA
Carvalho, V. F. M., Migotto, A., Giacone, D. V., Lemos, D. P. de, Zanoni, T. B., Maria-Engler, S. S., et al. (2017). Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models. European Journal of Pharmaceutical Sciences, 109, 131-143. doi:10.1016/j.ejps.2017.07.023
NLM
Carvalho VFM, Migotto A, Giacone DV, Lemos DP de, Zanoni TB, Maria-Engler SS, Lotufo LVC, Lopes LB. Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models [Internet]. European Journal of Pharmaceutical Sciences. 2017 ; 109 131-143.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ejps.2017.07.023
Vancouver
Carvalho VFM, Migotto A, Giacone DV, Lemos DP de, Zanoni TB, Maria-Engler SS, Lotufo LVC, Lopes LB. Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models [Internet]. European Journal of Pharmaceutical Sciences. 2017 ; 109 131-143.[citado 2024 jul. 10 ] Available from: https://doi.org/10.1016/j.ejps.2017.07.023
Trabalho de evento-resumo periodico
Multifunctional nanoemulsions promote cutaneous co-localization of chemotherapeutic agents and improve efficacy in 3D models of skin cancer (2017)
Dartora, Vanessa Franco Carvalho; Migotto, Amanda; Giacone, Daniela Veronesi; Zanoni, Thalita Boldrin; Maria-Engler, Silvya Stuchi ; Lotufo, Leticia Veras Costa ; Lopes, Luciana Biagini
Fonte: Brazilian Journal of Pharmaceutical Sciences. Nome do evento: Workshop on Melanoma Models. Unidades: FCF, ICB
Assunto: MELANOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DARTORA, Vanessa Franco Carvalho et al. Multifunctional nanoemulsions promote cutaneous co-localization of chemotherapeutic agents and improve efficacy in 3D models of skin cancer. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 10 jul. 2024. , 2017
APA
Dartora, V. F. C., Migotto, A., Giacone, D. V., Zanoni, T. B., Maria-Engler, S. S., Lotufo, L. V. C., & Lopes, L. B. (2017). Multifunctional nanoemulsions promote cutaneous co-localization of chemotherapeutic agents and improve efficacy in 3D models of skin cancer. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Dartora VFC, Migotto A, Giacone DV, Zanoni TB, Maria-Engler SS, Lotufo LVC, Lopes LB. Multifunctional nanoemulsions promote cutaneous co-localization of chemotherapeutic agents and improve efficacy in 3D models of skin cancer. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 30 res. WM-036.[citado 2024 jul. 10 ]
Vancouver
Dartora VFC, Migotto A, Giacone DV, Zanoni TB, Maria-Engler SS, Lotufo LVC, Lopes LB. Multifunctional nanoemulsions promote cutaneous co-localization of chemotherapeutic agents and improve efficacy in 3D models of skin cancer. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 30 res. WM-036.[citado 2024 jul. 10 ]
Trabalho de evento-resumo periodico
Prodigiosin and its derivatives as new options for melanoma treatment (2017)
Branco, Paola Cristina; Pontes, Cristine Araújo; Bauermeister, Anelize; Fernandes, Débora Kristina Alves; Hirata, Amanda Soares; Jimenez, Paula Christine; Lopes, Norberto Peporine; Maria-Engler, Silvya Stuchi ; Lotufo, Leticia Veras Costa
Fonte: Brazilian Journal of Pharmaceutical Sciences. Nome do evento: Workshop on Melanoma Models. Unidades: FCFRP, FCF, ICB
Assunto: MELANOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRANCO, Paola Cristina et al. Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 10 jul. 2024. , 2017
APA
Branco, P. C., Pontes, C. A., Bauermeister, A., Fernandes, D. K. A., Hirata, A. S., Jimenez, P. C., et al. (2017). Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo.
NLM
Branco PC, Pontes CA, Bauermeister A, Fernandes DKA, Hirata AS, Jimenez PC, Lopes NP, Maria-Engler SS, Lotufo LVC. Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 28 res. WM-031.[citado 2024 jul. 10 ]
Vancouver
Branco PC, Pontes CA, Bauermeister A, Fernandes DKA, Hirata AS, Jimenez PC, Lopes NP, Maria-Engler SS, Lotufo LVC. Prodigiosin and its derivatives as new options for melanoma treatment. Brazilian Journal of Pharmaceutical Sciences. 2017 ; 53 28 res. WM-031.[citado 2024 jul. 10 ]

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Título da fonte

Nome do evento

País de publicação

Grupo de pesquisa

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada